Clinical Trials
5 trialsNCT06887348 2026-01-12
RPx
Replimune, Inc.
Recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT05234177 2025-05-06
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Tempus AI
Recruiting
NCT05292443 2024-02-23
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Geneplus-Beijing Co. Ltd.
Withdrawn
NCT00759109 2017-04-07
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
Merck Sharp & Dohme LLC
Phase 3 Completed